Clinical trials: Depressive State
Major Depressive Disorder
A Study in Prevention of Re-emergence of Depression Symptoms
The primary objective of this study was to assess the maintenance of efficacy of LY2216684 compared with placebo as adjunctive therapy to selective serotonin reuptake inhibitors (SSRIs) as measured by the time-to-symptom…
- Trial name
- NCT01299272
- Testing
- LY2216684, SSRI
- Where
- 77 sites in United States, Argentina and 14 more
- Volunteers
- 1,249 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression
This study is a retrospective database study in Japan to evaluate the relative risk of serious intracranial hemorrhage requiring hospitalization between Vortioxetine tablet treatment and selective serotonin reuptake inhibitor…
- Trial name
- NCT05932407
- Testing
- Vortioxetine Tablet, SSRI
- Where
- Japan
- Volunteers
- 147,777 people
- Sponsor
- Takeda
Treatment Resistant Depression
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Treatment Durations From Ten Days to One Day
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression…
- Trial name
- NCT03986658
- Testing
- Linear Asymmetric rTMS System
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- NeuroQore Inc.
Major Depressive Disorders
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
Primary objective : To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode.
- Trial name
- NCT00825058
- Testing
- amibegron (SR58611A), paroxetine
- Where
- 8 sites in Bulgaria, Croatia and 6 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Major Depressive Disorder
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
The purpose of this study is to evaluate the efficacy and overall safety and tolerability of treatment with adjunctive JNJ-40411813 compared to placebo in patients with MDD with anxiety symptoms being treated with an…
- Trial name
- NCT01582815
- Testing
- JNJ-40411813
- Where
- 26 sites in Bulgaria, Hungary and 4 more
- Volunteers
- 121 people
- Sponsor
- Janssen Research & Development, LLC
Depression
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01309945
- Testing
- Duloxetine, BMS-820836
- Where
- 84 sites in United States, Canada and 4 more
- Volunteers
- 889 people
- Sponsor
- Bristol-Myers Squibb
Screen Time
Characterization of Smartphone-related Diseases Using the Phonix Care Application
The goal of this observational study is to describe how adolescents and young adults use screens in their daily lives and to identify different profiles of screen use ranging from low to excessive.
- Trial name
- PHX_2022_1 (NCT07293208)
- Testing
- PhonixDiag Smartphone Monitoring Tool
- Where
- France
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- Phonix Health
Depression
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subject
This study evaluates the safety, tolerability and pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Chinese healthy subjects
- Trial name
- NCT03850834
- Testing
- Ammoxetine Hydrochloride Enteric-coated Tablets
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Major Depressive Disorders
Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder
Primary objective: To evaluate the long-term safety and tolerability of SR58611A (amibegron) patients with major depressive disorder (MDD).
- Trial name
- NCT00855530
- Testing
- amibegron (SR58611A)
- Where
- 11 sites in Argentina, Chile and 9 more
- Volunteers
- 527 people
- Sponsor
- Sanofi
Depression
Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics of ascending single doses of BMS-866949 in healthy subjects.
- Trial name
- NCT00949767
- Testing
- BMS-866949
- Where
- Sweden
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01180400
- Testing
- TC-5214
- Where
- 66 sites in Czechia, Estonia and 8 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Postpartum Depressive Disorder
A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum Depression
This is a study evaluating the efficacy, and safety of KH607 in 72 participants diagnosed with Postpartum Depressive Disorder.
- Trial name
- NCT07096791
- Testing
- KH607 tablet
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Early Onset Alzheimer Disease, Mild Cognitive Impairment
Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain
Establishment of a BNA reference database for the Adult and Elderly Population. Hypothesis-generating study designed to collect data that will aid in future scientific and engineering exploration of correlations between clinical…
- Conditions
- Early Onset Alzheimer Disease, Mild Cognitive Impairment, Depression, Aging
- Trial name
- (BNA™) (NCT02875496)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
Depressive Disorder, Major
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
- Trial name
- NCT00445679
- Testing
- DVS SR, Paroxetine
- Where
- 43 sites in China, India and 2 more
- Volunteers
- 807 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fed and Fasted Conditions
To demonstrate the relative bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride capsules (Pulvules) in healthy adult males under fed and fasted conditions.
- Trial name
- NCT00913588
- Testing
- Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.), Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.), Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depressive Disorder
Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838876
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 90 sites in United States, Puerto Rico
- Volunteers
- 442 people
- Sponsor
- Forest Laboratories
COVID-19, Pregnancy Complications
Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic
The purpose of this study is to assess the health and wellbeing of pregnant and recently pregnant women during the COVID-19 pandemic using an online survey.
- Conditions
- COVID-19, Pregnancy Complications, Mental Health Wellness 1, Anxiety
- Trial name
- NCT04385238
- Testing
- This is an online survey with no intervention.
- Where
- United States
- Volunteers
- 6,894 people
- Sponsor
- Pregistry
Depressive Disorder, Depressive Symptoms
AI Mental Health Tool vs. Psychoeducation Control
The goal of this clinical trial is to learn if Ash, an AI chat tool for mental health, works better than static psychoedcuation in reducing mental health symptoms.
- Trial name
- NCT07841483
- Testing
- Ash, Psychoeducation
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Slingshot AI
Depressive Disorder, Major, Anxiety Disorders
Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)
Approximately 20 sites in Korea including the Catholic University of Korea, Yeouido St. Mary's Hospital. Patients with Depressive disorders taking a selective serotonin reuptake inhibitor (SSRI) antidepressant or Serotonin and…
- Trial name
- BASIS (NCT04770454)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd